LATEST NEWS

Latest News

Latest news is provided by our trusted partners at MJH Life Sciences® and its brands, and is not a publication of NMSCO.

FDA Awards Breakthrough Therapy Designation to TERN-701 for Pretreated Ph+ CP-CML

April 28, 2026

Riley Kandel

The FDA has granted breakthrough therapy designation to TERN-701 for the treatment of Ph-positive chronic myeloid leukemia in chronic phase.

Innovative Treatment Sequencing Strategies May Reshape HR+ Breast Oncology

April 28, 2026

Ashling Wahner

Rena D. Callahan, MD, discusses questions regarding treatment sequencing with CDK4/6 inhibitors and ADCs in hormone receptor–positive breast cancer.

Multidisciplinary Approaches and Managing Skin AEs are Crucial to CTCL Treatment

April 28, 2026

Riley Kandel

Stefan K. Barta, MD, MS, discusses the CTCL subtype myosis fungoides, common adverse effects, and optimal treatment approaches.

CLDN6-Targeted ADC QLS5132 Shows Promising Activity in Platinum-Resistant Ovarian Cancer

April 27, 2026

Caroline Seymour

QLS5132 led to a 50% ORR and manageable safety in PROC, supporting CLDN6 as a promising ADC target in early-phase clinical development.

Tovecimig Plus Paclitaxel Meets Secondary PFS End Point in Second-Line Biliary Tract Cancer

April 27, 2026

Courtney Flaherty

Tovecimig plus paclitaxel improved PFS vs paclitaxel alone in COMPANION-002, though crossover effects complicated OS outcomes.

Dana-Farber Cancer Institute Announces $5 Million Gift from Larry and Susan Marx for Cancer Prevention and Early Detection

April 27, 2026

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute announced a gift to support cancer prevention and establish the Larry and Susan Marx Chair for Early Detection.

FDA Grants Priority Review to Zanidatamab-Based Regimens in First-Line HER2+ GEA

April 27, 2026

Courtney Flaherty

The agency has set a target action date of August 25, 2026, for the sBLA, which is supported by data from the phase 3 HERIZON-GEA-01 trial.

Early-Phase Data With Zovegalisib/Atirmociclib/Fulvestrant Sets the Stage for Phase 3 Study in Breast Cancer

April 27, 2026

Ashling Wahner

Frontline treatment with zovegalisib, atirmociclib, and fulvestrant yielded responses in pretreated, PI3Kα-mutated HR-positive metastatic breast cancer.

Raising Testicular Cancer Awareness Enhances Treatment Decision-Making and Survivorship Care

April 27, 2026

Kyle Doherty

Mina M. Fam, MD, and Bradley McGregor, MD, discuss the treatment landscape of testicular cancer during Testicular Cancer Awareness Month.

Optimal HR+ Early Breast Cancer Care Must Weigh CDK4/6 Inhibitor Efficacy With Adherence

April 27, 2026

Ashling Wahner

Breast cancer experts discuss nuances of using CDK4/6 inhibitors to treat patients with high-risk hormone receptor–positive, HER2-negative early disease.

The Evolving Health Care Landscape and the Oncologist’s Role in Policy Engagement

April 27, 2026

Jill Gilbert, MD

In her latest OncologyFellows column, Jill Gilbert, MD, discusses how oncologists can influence large health care decisions and policy.

Five Under 5: Top Oncology Videos for the Week of 4/19

April 26, 2026

OncLive Staff

The top 5 OncLive TV videos of the week cover insights in head and neck cancer, esophageal cancer, renal cell carcinoma, and breast cancer.

Long-Term Data Expand the Horizon of Hormone Receptor+ Breast Cancer Therapies

April 26, 2026

Ashling Wahner

Rena D. Callahan, MD, discusses clinical considerations for CDK4/6 inhibitor–based regimens and oral SERDs in hormone receptor–positive breast cancer.

The OncFive: Top Oncology Articles for the Week of 4/19

April 25, 2026

OncLive Staff

The FDA grants priority review to enfortumab vedotin-ejfv sBLAs in MIBC, the review period for subcutaneous isatuximab BLA in myeloma has been extended, and more.

Real-World Data Support Use of CD19-Directed CAR T-Cell Therapy in R/R Primary Mediastinal B-Cell Lymphoma

April 25, 2026

Chris Ryan

Data from a real-world analysis demonstrated the efficacy and safety of CAR T-cell therapy in primary mediastinal B-cell lymphoma.